You are here: Industry Insights > NSCLC

News List

FDA expands first-line NSCLC label for Merck & Co.'s Keytruda firstwordpharma
April 12, 2019
FDA expands first-line NSCLC label for Merck & Co.'s Keytruda.
FDA expands first-line NSCLC label for Merck & Co.'s Keytruda firstwordpharma
April 12, 2019
FDA expands first-line NSCLC label for Merck & Co.'s Keytruda.
How Hot is the Third-generation EGFR-TKI? PharmaSources/Caicai
April 03, 2019
BPI-7711 is a third-generation EGFR-TKI, making Beta Pharma the fourth Chinese pharmaceutical enterprises that enter the Phase III clinical trial of the variety following ACEA, Hansoh, and Allist.
New lung cancer indication for Keytruda combo OK’d in EU pharmatimes
March 19, 2019
MSD’s anti-PD-1 therapy Keytruda has been approved for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for first-line treatment of adults with metastatic squamous non-small cell lung cancer (NSCLC).
Merck Provides Update on KEYTRUDA sBLA for KEYNOTE-042 Trial americanpharmaceuticalreview
December 29, 2018
Merck announced the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics License Application (sBLA) for KEYTRUDA.....
AstraZeneca’s tremelimumab fails another phase 3 cancer trial fiercebiotech
December 28, 2018
AstraZeneca’s tremelimumab has come up short in another phase 3 trial. Having failed to improve outcomes in metastatic non-small cell lung cancer (NSCLC).....
Keytruda approved for combination lung cancer therapy pharmaphorum
December 18, 2018
The US Food and Drug Administration (FDA) has approved Merck & Co’s Keytruda plus chemotherapy as a first-line treatment for non-small cell lung cancer (NSCLC).....
Innovent declares positive result of IBI305, biosimilar to Avastin biospectrumasia
December 17, 2018
“Anti-angiogenic drugs are effective anti-tumor treatments, but as of yet there are no approved bevacizumab biosimilars in China.
EC Approves Takeda’s ALUNBRIG for ALK+ Non-Small Cell Lung Cancer biospectrumasia
December 03, 2018
“The European Commission’s decision to approve ALUNBRIG for patients with ALK+ NSCLC is a significant advancement for European patients impacted by this life-threatening disease”
European approval for Takeda's Alunbrig in ALK+ advanced non-small cell lung cancer pharmafile
November 29, 2018
Takeda’s Alunbrig (brigatinib) has been granted marketing approval by the European Commission as a monotherapy to treat anaplastic lymphoma kinase-positive (ALK+) advanced non-small

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page